Other
Journal
About P&T Journal
Contacts:Editor:
ssherritze@medimedia.com
Advertising:
mliberti@medimedia.com
Circulation:
lgardineer@medimedia.com
Production:
wpeart@medimedia.com
Rate Card
Production Specifications
Statement of Purpose
Guidelines for Authors
Masthead
Editorial Board
Reprints
Recent Issues
March 2004
Features
Health Care and Law
Stem Cell Researchers Face an Unsettled Legal Environment
The author reviews the recent progress in the area of stem cell technology and discusses the obstacles to further development in the U.S..
Robert I. Field, JD, MPH, PhD
Pharmaceutical-Approval Update: Oncology
Three antineoplastic agents are described: intravenous cetuximab for metastatic colorectal cancer, injected pemetrexed for malignant pleural mesothelioma, and injected oxaliplatin for recurrent or metastatic colorectal cancer.
Marvin M. Goldenberg, PhD, RPh, MS
Safety and Tolerability of Tegaserod for Irritable Bowel Syndrome
Dr. Howden reviews tegaserod maleate (Zelnorm™) and its role in patients with multiple gastrointestinal problems.
Colin W. Howden, MD
Pharmacists’ Job Satisfaction: Variation by Practice Setting
Pharmacists respond to a nationwide survey about their likes and dislikes on the job.
Vittorio Maio, PharmD, MS, Neil I. Goldfarb, and Christine W. Hartmann, MSS
Meeting Highlights
Highlights of the American Stroke Association’s 29th International Stroke Conference
Dr. Prescott reports on a combined thrombolytic/glycoprotein receptor blocker
therapy for middle cerebral artery occlusion, a thrombin inhibitor, a low-dose thrombolytic agent, an astrocyte activation modulator, a new investigational agent, amphetamine therapy plus physiotherapy, statins for brain infarction, and recombinant factor VIIa for correcting warfarin anticoagulation.
Lawrence M. Prescott, PhD
Departments
Editorial
Follow-ups
David Nash, MD, MBA, discusses articles that followed up on themes in earlier P&T editorials on ALLHAT and counterfeit drugs.
David Nash, MD, MBA
Letters to the Editor
Editorial Board Spotlight
Meet Matt, Mister Medication Safety
Matthew Grissinger discusses his background in pharmacy and his role at the Institute for Safe Medication Practices.
Sonja Sherritze
Prescription Washington
Getting Drug Ads to Add Up: The FDA Thinks Less Is More
Stephen Barlas comments on the FDA’s draft guidance calling for clearer language in the “brief” summaries in drug package inserts.
Stephen Barlas
Medication Errors
Shedding “Lyte” on the Multifaceted Nature of Errors
Matthew Grissinger, RPh, FASCP, describes a mix-up that occurred when sodium acetate was confused with potassium acetate.
Matthew Grissinger, RPh, FASCP
New Drugs/Drug News/New Medical Devices
Drug Forecast
Memantine: A New Treatment Option for Patients with Moderate-to-Severe Alzheimer’s Disease
Yvonne Ho and Larisa Chagan review memantine
(Namenda™) for moderate-to-severe Alzheimer’s disease.
Yvonne Ho, PharmD Candidate, and Larisa Chagan, BS, PharmD, BCPS
P&T Snapshot
Hospitalization Patterns for Stroke
